| Size | Price | Stock | Qty |
|---|---|---|---|
| 10g |
|
||
| 50g |
|
||
| Other Sizes |
|
| ln Vitro |
As the concentration of CV in the growing medium grew, so did strain RB1's sensitivity to streptomycin. Cytochrome aa3 levels and streptomycin sensitivity both rise with increasing CV concentration in the growing medium. B. subtilis cannot accumulate streptomycin without cytochrome aa3 [1]. Streptomycin has an impact on tRNA selection. Mutations causing streptomycin resistance often localize to protein S12, and the majority of these variations show increased discrimination during tRNA selection [2].
|
|---|---|
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Summary of Use during Lactation Similar to other aminoglycoside antibiotics, streptomycin is poorly excreted into breastmilk. Newborn infants apparently absorb small amounts of aminoglycosides, but serum levels are far below those attained when treating newborn infections and systemic effects of streptomycin are unlikely. Older infants would be expected to absorb even less streptomycin Monitor the infant for possible effects on the gastrointestinal flora, such as diarrhea, candidiasis (e.g., thrush, diaper rash) or rarely, blood in the stool indicating possible antibiotic-associated colitis. ◉ Effects in Breastfed Infants Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk One observational study found no inhibition of lactation by streptomycin. |
| References | |
| Additional Infomation |
Streptomycin Sulfate can cause developmental toxicity according to state or federal government labeling requirements.
Streptomycin sulfate (2:3) (salt) appears as an antibacterial. White to light gray or pale buff powder with faint amine-like odor. Streptomycin sulfate is an aminoglycoside sulfate salt. It is functionally related to a streptomycin. Streptomycin Sulfate is the sulfate salt form of streptomycin, an aminoglycoside antibiotic derived from Streptomyces griseus with antibacterial property. Streptomycin sulfate binds to the S12 protein of the bacterial 30S ribosomal subunit, thereby inhibiting peptide elongation and protein synthesis, consequently leading to bacterial cell death. An antibiotic produced by the soil actinomycete Streptomyces griseus. It acts by inhibiting the initiation and elongation processes during protein synthesis. See also: Streptomycin (has active moiety) ... View More ... |
| Exact Mass |
1456.433
|
|---|---|
| CAS # |
3810-74-0
|
| Related CAS # |
Streptomycin;57-92-1
|
| PubChem CID |
19648
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
948.2ºC at 760 mmHg
|
| Flash Point |
527.3ºC
|
| Index of Refraction |
-85 ° (C=1, H2O)
|
| Hydrogen Bond Donor Count |
30
|
| Hydrogen Bond Acceptor Count |
42
|
| Rotatable Bond Count |
18
|
| Heavy Atom Count |
95
|
| Complexity |
1020
|
| Defined Atom Stereocenter Count |
30
|
| SMILES |
S(=O)(=O)(O[H])O[H].S(=O)(=O)(O[H])O[H].S(=O)(=O)(O[H])O[H].O([C@@]1([H])[C@@]([H])([C@@](C([H])=O)([C@]([H])(C([H])([H])[H])O1)O[H])O[C@@]1([H])[C@]([H])([C@@]([H])([C@]([H])([C@]([H])(C([H])([H])O[H])O1)O[H])O[H])N([H])C([H])([H])[H])[C@@]1([H])[C@@]([H])([C@]([H])([C@@]([H])([C@]([H])([C@]1([H])/N=C(\N([H])[H])/N([H])[H])O[H])/N=C(\N([H])[H])/N([H])[H])O[H])O[H].O([C@@]1([H])[C@@]([H])([C@@](C([H])=O)([C@]([H])(C([H])([H])[H])O1)O[H])O[C@@]1([H])[C@]([H])([C@@]([H])([C@]([H])([C@]([H])(C([H])([H])O[H])O1)O[H])O[H])N([H])C([H])([H])[H])[C@@]1([H])[C@@]([H])([C@]([H])([C@@]([H])([C@]([H])([C@]1([H])/N=C(\N([H])[H])/N([H])[H])O[H])/N=C(\N([H])[H])/N([H])[H])O[H])O[H]
|
| InChi Key |
QTENRWWVYAAPBI-YCRXJPFRSA-N
|
| InChi Code |
InChI=1S/2C21H39N7O12.3H2O4S/c2*1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35;3*1-5(2,3)4/h2*4-18,26,29,31-36H,3H2,1-2H3,(H4,22,23,27)(H4,24,25,28);3*(H2,1,2,3,4)/t2*5-,6-,7+,8-,9-,10-,11+,12-,13-,14+,15+,16-,17-,18-,21+;;;/m00.../s1
|
| Chemical Name |
2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine;sulfuric acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 100 mg/mL (~137.23 mM)
DMSO :< 1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (137.23 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00004444 | COMPLETED | Drug: paromomycin Drug: streptomycin |
Tuberculosis, Pulmonary | FDA Office of Orphan Products Development | 1994-11 | Not Applicable |
| NCT00128466 | COMPLETED | Drug: gentamicin Drug: streptomycin |
Plague | Centers for Disease Control and Prevention | 2004-08 | Phase 2 Phase 3 |
| NCT01432925 | COMPLETED | Procedure: surgical intervention on Buruli ulcer | Buruli Ulcer Mycobacterium Ulcerans Disease |
University Medical Center Groningen | 2011-09 | Not Applicable |
| NCT04110340 | RECRUITING | Drug: Ciprofloxacin Drug: Streptomycin Drug: Gentamicin |
Plague, Bubonic Plague, Pneumonic |
University of Oxford | 2020-02-15 | Phase 3 |
| NCT02604849 | COMPLETED | Drug: Neomycin Drug: Streptomycin Drug: Gentamicins |
Patients Colonized by Klebsiella Pneumoniae |
Maimónides Biomedical Research Institute of Córdoba | 2012-07 |
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
